High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer
High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer
复制标题
DOI：
10.1016/j.oraloncology.2009.12.007
复制
发表时间：
2010-03-01
期刊：
影响因子：
4.8
通讯作者：
Sheen, Seung Soo
中科院分区：
文献类型：
--
作者：
Lee, Hyun Woo;Hwang, Yoon Ho;Sheen, Seung Soo
我们评估了切除修复交叉互补组1蛋白（ERCC 1）和胸苷酸合成酶（TS）在同步放化疗（CCRT）治疗的鼻咽癌（NPC）患者中的预后意义。采用免疫组织化学方法分析41例局部晚期鼻咽癌患者（I期：1例，II期：10例，III期：9例，IV期：21例）治疗前肿瘤活检标本中ERCC 1和TS的表达。所有患者均接受一个周期的诱导化疗（5-氟尿嘧啶1000 mg/m2/d和顺铂20 mg/m2/d，第1-4天），然后从第22天开始接受CCRT。CCRT包括放疗（70戈伊/35次，共7周）和顺铂20 mg/m2/天，在放疗的第1、4和7周持续4天。ERCC 1和TS分别在25例（60%）和21例（51%）患者中观察到高表达。ERCC 1的高表达与WHO 1型或2型组织学相关（p = 0.045）。生存者的中位随访时间为106个月（32-152个月），所有患者的5年总生存率（OS）为53%。在单变量分析中，ERCC 1高表达患者的5年OS（73% vs 39%，p = 0.005）显著较差，而TS高表达与患者结局无关。在多变量分析中，ERCC 1的高表达是OS差的显著独立预后因素（p = 0.029），沿着WHO 1型或2型组织学。ERCC 1蛋白的高表达可能是局部晚期鼻咽癌患者接受CCRT治疗后预后不良的一个有用的预后因素。(C)2009爱思唯尔有限公司保留所有权利。
We evaluated the prognostic significance of excision repair cross-complementation group 1 protein (ERCC1) and thymidylate synthase (TS) in patients with nasopharyngeal cancer (NPC) treated with concurrent chemoradiotherapy (CCRT). Pre-treatment tumor biopsy specimens from 41 patients with locally advanced NPC (stage I: 1, II: 10, III: 9, IV: 21 patients) were analyzed for ERCC1 and TS expression by immunohistochemistry. All patients were treated with one cycle of induction chemotherapy (5-fluorouracil 1000 mg/m(2)/day and cisplatin 20 mg/m(2)/day, days 1-4) followed by CCRT starting on day 22. CCRT consisted of radiotherapy (70 Gy/35 fractions for 7 weeks) with cisplatin 20 mg/m(2)/day for 4 days on weeks 1, 4, and 7 of radiotherapy. High expression of ERCC1 and TS was observed in 25 (60%) and 21 (51%) patients, respectively. High expression of ERCC1 was associated with WHO type 1 or 2 histology (p = 0.045). With a median follow-up duration of 106 months (32-152 months) in survivors, the 5-year overall survival (OS) of all patients was 53%. In univariate analysis, 5-year OS (73% versus 39%, p = 0.005) was significantly inferior in patients with high expression of ERCC1, while high expression of TS was not correlated with patient outcome. In multivariate analysis, high expression of ERCC1 was a significant independent prognostic factor for poor OS (p = 0.029) along with WHO type 1 or 2 histology. High expression of ERCC1 protein may be a useful prognostic factor for poor outcome in patients with locally advanced NPC treated with CCRT. (C) 2009 Elsevier Ltd. All rights reserved.